Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Results 2026-05-21
Interim MD&A - English.pdf
Results 2026-05-21
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2026 AND SCHEDULES MAY 25, 2026 CONFERENCE CALL
News release - English.pdf
Results 2026-05-21
Interim financial statements/report – English.pdf
Results 2026-04-23
Annual report on form 20-F - English.pdf
Results 2026-04-23
Annual MD&A - English.pdf
Results 2026-04-23
Audited annual financial statements – English.pdf
Results 2026-04-23
Medicure Reports Financial Results For The Year Ended December 31, 2025 And Schedules April 27, 2026 Conference Call
News release - English.pdf
Results 2025-11-19
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2025
News release - English.pdf
Results 2025-11-19 Financials
Interim MD&A - English.pdf
Results 2025-11-19 Financials
Interim financial statements/report – English.pdf
News 2025-11-13
News release - English.pdf
Results 2025-08-20 Financials
Interim financial statements/report – English.pdf
Results 2025-08-20 Financials
Interim MD&A - English.pdf
News 2025-08-20
News release - English.pdf
News 2025-08-18
News release - English.pdf
News 2025-06-17
News release - English.pdf